ClinicalTrials.gg
Sign In

Thrombocythemia, Essential clinical trials

The registry lists 229 studies for Thrombocythemia, Essential across more than 10 countries. 38 are recruiting or about to start. 49 of them are mainly about Thrombocythemia, Essential (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.

Get an email when these change. Save the Thrombocythemia, Essential studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
131
Recruiting
34
Terminated
25
Active, not recruiting
20
Status unknown
8
Withdrawn
7

Phase

Phase 2
88
Phase 1
68
Phase 3
31
Phase 4
3
Early Phase 1
2

Where

United States
149
Italy
38
France
37
United Kingdom
29
Germany
28
Canada
20

Who runs them

National Cancer Institute (NCI) (13) · Fred Hutchinson Cancer Center (13) · Incyte Corporation (8) · Shire (8) · M.D. Anderson Cancer Center (6) · Icahn School of Medicine at Mount Sinai (5) · Mayo Clinic (5) · AOP Orphan Pharmaceuticals AG (4)

What is being tested here

Drugs under test in Thrombocythemia, Essential studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Peginterferon alfa-2b314
Ruxolitinib219
Pacritinib226
Anti-mutant Calreticulin Monoclonal Antibody INCA033989213
Bomedemstat137
Decitabine105
Melphalan113
Methotrexate103
Fedratinib101
Dencatistat101

Drug classes tested here Antimetabolites 3 open · Tyrosine kinase inhibitors (TKIs) 3 open · JAK inhibitors 3 open · Alkylating agents 1 open · PARP inhibitors 1 open

Coming up

8phase 3 studies under way
21studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 34 Thrombocythemia, Essential studies recruiting now, 30 (88%) set no upper age limit and 3 (9%) stop at 75 or younger. 5 (15%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (6%) take healthy volunteers.

Recruiting studies that take each age, of 34
AgeWomenMen
104 (12%)4 (12%)
1833 (97%)33 (97%)
3032 (94%)32 (94%)
4032 (94%)32 (94%)
5032 (94%)32 (94%)
6531 (91%)31 (91%)
7531 (91%)31 (91%)
8531 (91%)31 (91%)

Across all 229 studies, recruiting or not: 19% stop at 75 or younger and 11% at 65; 24% take children; 0% are for women only and 0% for men only; 3% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Thrombocythemia, Essential studies take

Of 27 phase 2 interventional studies under Thrombocythemia, Essential, half reached primary completion within 64 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 264 mo32–141 · 27 studies——
Observational35 mo26–75 · 15 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 229. Browse all 229 → or search them.